Metformin Is the First Choice in Type 2 Meds
Initiating the treatment of type 2 diabetes with metformin is associated with a lower long-term risk of heart attack, stroke, and death than starting with a sulfonylurea, researchers report. It's not known whether the difference is due to additional risk from sulfonylureas, benefits from metformin, or both. The results back up expert recommendations that metformin be considered first in the treatment of type 2. Another study compared two newer type 2 medications, once-weekly exenatide (Bydureon) and liraglutide (Victoza). It found that both injectable drugs lowered blood glucose levels while helping users lose weight. Liraglutide was associated with slightly greater reductions in blood glucose and weight, while weekly exenatide had fewer side effects, such as nausea.
Sources: Annals of Internal Medicine, Nov. 6, 2012; The Lancet, published online Nov. 7, 2012